Blood Based Biomarkers Global Market Report 2025

The blood-based biomarkers market size has grown rapidly in recent years. It will grow from $23.13 billion in 2024 to $26.06 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth observed in the past can be attributed to the increasing global incidence of cancer, a higher adoption of personalized medicine, more funding in biomarker research, a rise in clinical trials involving biomarkers, and an increase in the approval of companion diagnostics.

The blood-based biomarkers market size is expected to see rapid growth in the next few years. It will grow to $41.55 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth during the forecast period is expected to be driven by the expansion of AI and machine learning in biomarker analysis, a higher demand for early disease detection, the growth of telemedicine and remote diagnostics, the increasing prevalence of chronic diseases, and greater health awareness among consumers. Key trends during this period will include AI-driven biomarker discovery, advancements in liquid biopsy, integration of multi-omics, development of point-of-care (POC) testing devices, and innovations in next-generation sequencing (NGS).

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the blood-based biomarkers market. Cardiovascular diseases, which encompass disorders affecting the heart and blood vessels such as coronary artery disease, heart failure, and stroke, are becoming more common due to risk factors such as poor diet and rising obesity rates. Blood-based biomarkers play a crucial role in diagnosing and monitoring these diseases by offering valuable information on disease progression, risk assessment, and treatment response through measurable substances in the blood. A global health research initiative by the National Center for Biotechnology Information in September 2024 projected a 90% increase in cardiovascular disease cases from 2025 to 2050, with cardiovascular deaths expected to reach 35.6 million by 2050. This rising incidence of cardiovascular diseases is contributing to the market growth for blood-based biomarkers.

Leading companies in the blood-based biomarkers market are focusing on technological innovations, such as high-accuracy blood biomarker tests, to assist in diagnosing diseases such as Alzheimer’s disease. These tests use specific biomarkers in the blood to detect or monitor health conditions with high precision and reliability. For example, in October 2023, Quanterix, a US-based life sciences company, introduced the LucentAD p-Tau 217 test, a high-accuracy blood biomarker test designed to help physicians diagnose Alzheimer’s disease in adults with cognitive impairment. The test measures phosphorylated tau protein at threonine 217 (p-Tau 217), which is strongly linked to Alzheimer’s pathology, particularly amyloid buildup in the brain. The LucentAD p-Tau 217 test provides over 90% accuracy, fulfilling stringent diagnostic criteria, and is meant to be used alongside other diagnostic tools rather than independently.

In December 2023, Danaher, a US-based provider of diagnostic, life sciences, and environmental solutions, acquired Abcam for $5.7 billion. This acquisition allows Danaher to enhance its life sciences portfolio by incorporating Abcam’s leading protein consumables and research tools. Abcam, a UK-based life sciences company, specializes in the development and distribution of research tools, including antibodies, assays, and reagents.

Major players in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG.

North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in blood-based biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the blood-based biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Blood-based biomarkers are substances in the blood that can be measured to indicate the presence, progression, or response to a disease. They are primarily used for early detection, helping to personalize treatment plans and monitor treatment effectiveness with minimal invasiveness.

These biomarkers can be categorized into several types, including genetic, protein, metabolic, cell-based, and epigenetic biomarkers. Genetic biomarkers, which are based on DNA or RNA, identify genetic variations, mutations, or expression patterns linked to specific diseases or treatment responses. They are utilized in various advanced technologies, such as next-generation sequencing, polymerase chain reaction, immunoassays, and mass spectrometry. These biomarkers play a critical role in diagnosing and monitoring diseases such as cancer, cardiovascular conditions, neurological disorders, and immunological diseases. Key users of these biomarkers include hospitals, clinics, diagnostic labs, research institutes, and other healthcare providers.

The blood-based biomarkers market research report is one of a series of new reports that provides blood-based biomarkers market statistics, including the blood-based biomarkers industry global market size, regional shares, competitors with the blood-based biomarkers market share, detailed blood-based biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the blood-based biomarkers industry. This blood-based biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The blood-based biomarkers market consists of revenues earned by entities by providing services such as clinical trial services, sample collection and biobanking services, custom biomarker assay development, data analysis and interpretation services, companion diagnostics services, point-of-care testing services, and regulatory and compliance support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood-based biomarkers market includes sales of diagnostic kits, reagents, assay platforms, analyzers, and related consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.